XFOWW Projected Dividend Yield

X4 Pharmaceuticals Inc ( OTCBB : XFOWW )

X4 Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary product candidate is mavorixafor, a small molecule chemokine receptor type 4 (CXCR4) antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Co. is conducting clinical trials of mavorixafor: for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene; and in people with chronic neutropenia and Waldenstrom's macroglobulinemia, a rare B-cell lymphoproliferative disorder.

20 YEAR PERFORMANCE RESULTS